- Report
- October 2022
- 74 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 80 Pages
Africa
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 40 Pages
Brazil
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
China
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
France
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
Germany
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
Ireland
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
Russia
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
South Korea
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
United States
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2022
- 40 Pages
Vietnam
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP

Prostatic Hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing urinary symptoms such as difficulty urinating, frequent urination, and a weak urine stream. Prostate cancer drugs are used to treat BPH, as well as to reduce the risk of prostate cancer. These drugs work by blocking the action of testosterone, which can cause the prostate to enlarge. Commonly used drugs include alpha-blockers, 5-alpha reductase inhibitors, and anti-androgens. Alpha-blockers relax the muscles of the bladder neck and prostate, allowing for easier urination. 5-alpha reductase inhibitors reduce the production of dihydrotestosterone, which can cause prostate enlargement. Anti-androgens block the action of testosterone on the prostate.
Companies in the Prostatic Hyperplasia Drug market include Astellas Pharma, Merck, Pfizer, GlaxoSmithKline, and Sanofi. Show Less Read more